

Head Office

Pushpak, 1st Floor
Panchvati Circle
Motilal Hirabhai Road
Ahmedabad 380006
Gujarat, India
Phone +91 79 26445106

Factory

Village Merda-Ardraj
Taluka Kadi
District Mehsana
Gujarat 382721, India
Phone +91 2764 285 502
+91 2764 285 453

Email mail@hester.in
Toll Free 1 800 233 7937
www.hester.in

CIN L99999GJ1987PLC022333

7 November 2023

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

To,
National Stock Exchange of India Limited
Exchange Plaza,
Bandra - Kurla Complex,
Bandra (E), Mumbai 400 051

Scrip Code: 524669

Symbol: HESTERBIO

Dear Sir/ Madam:

Subject: Outcome of Board Meeting

This is with reference to our letter dated 27 October 2023 intimating the date of the Board Meeting for consideration of the unaudited standalone and consolidated financial results for the quarter and half year ended 30 September 2023.

Pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that Board of Directors, in their Meeting held today, have approved the unaudited standalone and consolidated financial results for the quarter and half year ended 30 September 2023, as recommended by Audit Committee.

We attach herewith:

- 1) The approved unaudited standalone and consolidated financial results and limited review reports
- 2) A Press Release issued in this regard

We will be publishing an extract of the results in the newspaper as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Board Meeting commenced at 11:19 a.m. (IST) and concluded at 12:16 p.m. (IST).

You are requested to take the above information on your record.

Sincerely
For Hester Biosciences Limited

Vinod Mali
Company Secretary & Compliance Officer

Enclosure: As above

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS PERIOD ENDED 30 SEPTEMBER 2023

Amount in ₹ Million

Sr. No.	Particulars	Quarter Ended			Six Months Period Ended		Year Ended
		30 September 2023	30 June 2023	30 September 2022	30 September 2023	30 September 2022	31 March 2023
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	Income						
1	Revenue from Operations	664.33	803.45	720.03	1,467.78	1,225.31	2,540.00
2	Other Income	12.20	8.59	21.77	20.79	34.11	53.23
3	Total income	676.53	812.04	741.80	1,488.57	1,259.42	2,593.23
4	Expenses						
	(a) Cost of material consumed	84.31	84.34	74.17	168.65	140.24	292.81
	(b) Purchases of stock-in-trade	116.84	177.47	139.09	294.31	225.38	553.71
	(c) Change in inventories of finished goods, traded goods and work in progress	2.58	81.62	8.49	84.20	23.18	(47.71)
	(d) Employee benefits expense	146.60	141.28	130.41	287.88	229.60	479.17
	(e) Finance cost	14.75	9.42	17.43	24.17	30.12	64.97
	(f) Depreciation and amortisation expense	25.78	25.48	23.37	51.26	47.30	97.88
	(g) Other expenses	194.07	205.09	210.05	399.16	357.11	713.16
	Total expenses	584.93	724.70	603.01	1,309.63	1,052.93	2,153.99
5	Profit before tax	91.60	87.34	138.79	178.94	206.49	439.24
6	Tax Expense						
	Current tax	24.84	23.67	35.24	48.51	55.41	107.27
	Deferred tax	(1.06)	(1.04)	0.10	(2.10)	(2.42)	8.55
	Total tax expense	23.78	22.63	35.34	46.41	52.99	115.82
7	Profit after tax	67.82	64.71	103.45	132.53	153.50	323.42
8	Other Comprehensive Income						
	Items that will not be reclassified to Profit or Loss						
	Remesurement Gain/(Loss) on Defined Benefit Plans	0.37	0.38	0.24	0.75	(0.29)	1.51
	Income tax impact	(0.10)	(0.09)	(0.06)	(0.19)	0.07	(0.38)
	Total Other Comprehensive Income	0.27	0.29	0.18	0.56	(0.22)	1.13
9	Total Comprehensive Income for the period / year	68.09	65.00	103.63	133.09	153.28	324.55
10	Paid-up equity share capital						85.07
11	Other Equity						2,838.75
12	Earnings Per Share (Face Value of INR 10 each) (Not Annualised) - Basic & Diluted (₹)	7.97	7.61	12.16	15.58	18.04	38.02

STATEMENT OF UNAUDITED STANDALONE ASSETS AND LIABILITIES AS AT 30 SEPTEMBER 2023		
Amount in ₹ Million		
Particulars	As at 30 September 2023	As at 31 March 2022
ASSETS		
Non-current assets		
(a) Property Plant & Equipment	1,040.74	1,078.46
(b) Capital Work-in-Progress	1,619.00	1,461.38
(c) Other Intangible Assets	4.56	3.71
(d) Intangible Assets under Development	23.44	24.69
(e) Financial Assets		
(i) Investments	646.89	646.89
(ii) Other Financial Assets	50.12	45.29
(f) Other Non-current Assets	7.47	37.25
Total Non-current Assets	3,392.22	3,297.67
Current assets		
(a) Inventories	725.10	792.16
(b) Financial Assets		
(i) Trade Receivables	1,046.55	823.60
(ii) Cash and Cash Equivalents	16.32	43.01
(iii) Bank Balances other than (ii) above	14.14	16.61
(iv) Loans	56.67	58.47
(v) Other Financial Assets	172.42	166.46
(c) Other Current Assets	218.73	260.17
Total Current Assets	2,249.93	2,160.48
Total Assets	5,642.15	5,458.15
EQUITY AND LIABILITIES		
Equity		
(a) Share capital	85.07	85.07
(b) Other equity	2,903.79	2,838.75
Total Equity	2,988.86	2,923.82
Liabilities		
Non-current liabilities		
(a) Financial Liabilities		
(i) Borrowings	877.34	833.97
(ii) Other Financial Liabilities	7.03	7.03
(b) Non Current Provision	19.79	17.16
(c) Deferred Tax Liabilities (Net)	69.37	71.47
(d) Other Non Current Liabilities	480.00	240.00
Total Non-current Liabilities	1,453.53	1,169.63
Current liabilities		
(a) Financial Liabilities		
(i) Borrowings	741.44	809.25
(ii) Trade Payables		
-Total outstanding dues of micro enterprises and small enterprises	4.47	4.56
-Total outstanding dues of creditors other than micro enterprises and small enterprises	275.59	282.55
(iii) Other Financial Liabilities	118.42	130.39
(b) Other Current Liabilities	27.20	99.66
(c) Provisions	6.27	4.42
(d) Current Tax Liabilities	26.37	33.87
Total Current Liabilities	1,199.76	1,364.70
Total Liabilities	2,653.29	2,534.33
Total Equity and Liabilities	5,642.15	5,458.15

STATEMENT OF UNAUDITED STANDALONE CASH FLOWS FOR SIX MONTHS PERIOD ENDED 30 SEPTEMBER 2023

Amount in ₹ Million

Particulars	Six Months Period Ended	
	30 September 2023	30 September 2022
	Unaudited	Unaudited
A. Cash Flow from operating activities		
Profit before tax	178.94	206.49
Adjustments for:		
Depreciation and amortisation Expense	51.26	47.30
Provision for doubtful debt	6.21	1.85
Bad debts written off	-	0.26
(Profit) / Loss on sale of property, plant & equipment	(0.09)	(0.16)
Interest expense	22.81	9.11
Unrealised foreign exchange loss / (gain)	1.89	21.47
Interest income	(8.54)	(11.25)
Operating profit before working capital changes	252.48	275.07
Adjustments for:		
Trade receivables	(231.05)	(164.41)
Inventories	67.06	(0.06)
Other assets	41.44	(25.00)
Trade payables	(7.05)	78.31
Other current liabilities	(72.46)	1.45
Provisions	4.48	4.35
Loans	1.80	(2.15)
Other financial Liability	(0.48)	1.26
Other financial assets	(0.81)	2.70
Cash Generated from Operations	55.41	171.52
Income tax paid (net)	(56.20)	(40.39)
Net cash generated from operating activities (A)	(0.79)	131.13
B. Cash flow from investing activities		
Capital expenditure on Property, Plant and Equipment, including capital advances and capital work-in-progress and on intangible assets	(123.71)	(551.26)
Proceeds from Sale of Property, Plant and Equipment	0.18	0.26
Interest received	2.45	2.95
Bank / margin money deposits withdrawn / (Investment) (Net)	(0.67)	8.55
Net cash used in investing activities (B)	(121.75)	(539.50)
C. Cash flow from financing activities		
Proceeds from long term borrowings	192.34	227.81
Repayment of long term borrowings	(108.90)	(36.52)
Proceeds/(Repayment) of Short-term Borrowings (net)	(108.13)	83.92
Government grant received	240.00	240.00
Interest Paid	(51.41)	(18.02)
Dividend Paid	(68.05)	(85.07)
Net cash generated from financing activities (C)	95.85	412.12
Net increase in cash and cash equivalents (A) + (B) + (C)	(26.69)	3.75
Cash and cash equivalents at the beginning of the year	43.01	15.28
Cash and cash equivalents at the end of the year	16.32	19.03

Notes:

- 1 The standalone financial results of Hester Biosciences Limited (the "Company") have been reviewed by the Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 7 November 2023.
- 2 The Statutory Auditors have carried out limited review of the standalone financial results of the Company for the quarter and six months period ended 30 September 2023.
- 3 Following are the details of segment wise revenue, results, segment assets and liabilities:

Amount in ₹ Million

Particulars	Quarter Ended			Six Months Period Ended		Year Ended
	30 September 2023	30 June 2023	30 September 2022	30 September 2023	30 September 2022	31 March 2023
Segment Revenue						
a. Poultry Healthcare	346.85	302.88	354.52	649.73	738.22	1,426.85
b. Animal Healthcare	308.07	224.66	360.75	532.73	481.51	1,006.79
c. Petcare	9.41	8.02	4.76	17.43	5.58	17.67
d. Others	-	267.89	-	267.89	-	88.69
Total Revenue from Operations	664.33	803.45	720.03	1,467.78	1,225.31	2,540.00
Segment Results						
a. Poultry Healthcare	38.11	27.89	80.28	66.00	165.54	270.53
b. Animal Healthcare	74.86	15.11	123.02	89.97	107.56	253.86
c. Petcare	(1.33)	(1.68)	(3.37)	(3.01)	(2.90)	(3.99)
d. Others	-	68.87	-	68.87	-	34.37
Total Segment Results	111.64	110.19	199.93	221.83	270.20	554.77
a. Finance Costs	14.75	9.42	17.43	24.17	30.12	64.97
b. Other unallocable expenditure/(income) (Net)	5.29	13.43	43.71	18.72	33.59	50.56
Profit before Tax	91.60	87.34	138.79	178.94	206.49	439.24
Segment Assets						
a. Poultry Healthcare	2,282.18	2,315.99	2,556.28	2,282.18	2,556.28	2,346.50
b. Animal Healthcare	606.48	500.84	476.46	606.48	476.46	583.71
c. Petcare	19.07	13.94	10.57	19.07	10.57	13.86
d. Others	234.59	250.05	-	234.59	-	112.60
Unallocated Assets	2,499.83	2,367.62	1,871.32	2,499.83	1,871.32	2,401.48
Total	5,642.15	5,448.44	4,914.63	5,642.15	4,914.63	5,458.15
Segment Liabilities						
a. Poultry Healthcare	165.30	166.45	137.13	165.30	137.13	166.02
b. Animal Healthcare	133.17	122.87	78.77	133.17	78.77	160.18
c. Petcare	0.19	0.19	0.37	0.19	0.37	0.57
d. Others	13.11	34.76	-	13.11	-	88.36
Unallocated Liabilities	2,341.52	2,135.35	1,945.81	2,341.52	1,945.81	2,119.20
Total	2,653.29	2,459.62	2,162.08	2,653.29	2,162.08	2,534.33

Notes:

a. Others segment include sale of other Pharmaceutical products.

b. Unallocated assets and liabilities includes capital work in-progress, capital advances and capital creditors related to Human Vaccine Project as the same is yet to be capitalised.

For and on behalf of the Board of Directors


Rajiv Gandhi
 CEO & Managing Director
 DIN: 00438037

 Place: Ahmedabad
 Date: 7 November 2023

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS PERIOD ENDED 30 SEPTEMBER 2023

Amount in ₹ Million

Sr. No.	Particulars	Quarter Ended			Six Months Period Ended		Year Ended
		30 September 2023	30 June 2023	30 September 2022	30 September 2023	30 September 2022	31 March 2023
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	Income						
1	Revenue from Operations	704.55	878.53	731.53	1,583.08	1,238.48	2,660.91
2	Other Income	43.58	11.45	44.49	55.03	75.72	151.51
3	Total income	748.13	889.98	776.02	1,638.11	1,314.20	2,812.42
4	Expenses						
	(a) Cost of material consumed	142.86	122.22	135.12	265.08	256.44	529.88
	(b) Purchases of stock-in-trade	60.23	144.26	71.67	204.49	100.91	297.49
	(c) Change in inventories of finished goods, traded goods and work in progress	(7.83)	75.23	12.70	67.40	11.43	(52.51)
	(d) Employee benefits expense	164.49	159.98	150.98	324.47	269.45	560.20
	(e) Finance cost	80.75	25.68	24.55	106.43	40.56	93.20
	(f) Depreciation and amortisation expense	42.84	53.99	50.30	96.83	100.90	206.95
	(g) Other expenses	212.65	233.21	233.61	445.86	398.50	819.76
	Total expenses	695.99	814.57	678.93	1,510.56	1,178.19	2,454.97
5	Profit before Share of Profit of Joint Venture entity and Tax	52.14	75.41	97.09	127.55	136.01	357.45
6	Share of Profit in Joint Venture entity	15.49	13.71	5.63	29.20	21.34	44.09
7	Profit before tax	67.63	89.12	102.72	156.75	157.35	401.54
8	Tax Expense						
	Current tax	26.74	23.99	36.86	50.73	57.92	112.78
	Deferred tax	0.48	(1.97)	(0.17)	(1.49)	(2.20)	8.41
	Total tax Expense	27.22	22.02	36.69	49.24	55.72	121.19
9	Profit after tax	40.41	67.10	66.03	107.51	101.63	280.35
10	Other Comprehensive Income						
	Items that will not be reclassified to Profit or Loss						
	Remeasurement Gain/(Loss) on Defined Benefit Plans	0.37	0.38	0.24	0.75	(0.29)	1.47
	Income tax impact	(0.10)	(0.09)	(0.06)	(0.19)	0.07	(0.37)
	Items that will be reclassified to Profit or Loss						
	Foreign Currency Translation Reserve	(5.96)	(4.13)	8.28	(10.09)	17.15	15.15
	Income Tax Impact	-	-	-	-	-	-
	Total Other Comprehensive Income	(5.69)	(3.84)	8.46	(9.53)	16.93	16.25
11	Total Comprehensive Income for the period/year	34.72	63.26	74.49	97.98	118.56	296.60
12	Profit for the period/year attributable to:						
	(i) Owners of the Company	40.86	58.69	69.42	99.55	109.10	266.27
	(ii) Non Controlling Interest	(0.45)	8.41	(3.39)	7.96	(7.47)	14.08
13	Other Comprehensive Income for the period/year attributable to:						
	(i) Owners of the Company	(5.69)	(3.84)	8.46	(9.53)	16.93	16.26
	(ii) Non Controlling Interest	-	-	-	-	-	(0.01)
14	Total Comprehensive Income for the period/year attributable to:						
	(i) Owners of the Company	35.17	54.85	77.88	90.02	126.03	282.53
	(ii) Non Controlling Interest	(0.45)	8.41	(3.39)	7.96	(7.74)	14.07
15	Paid-up equity share capital						85.07
16	Other Equity						2,712.23
17	Earnings Per Share (Face Value of ₹ 10 each) (Not Annualised) - Basic & Diluted (₹)	4.75	7.89	7.77	12.64	11.95	32.96

STATEMENT OF UNAUDITED CONSOLIDATED ASSETS AND LIABILITIES AS AT 30 SEPTEMBER 2023

Amount in ₹ Million

Particulars	As at 30 September 2023	As at 31 March 2023
ASSETS		
Non-current assets		
(a) Property Plant & Equipment	2,449.49	2,589.01
(b) Capital Work-in-Progress	1,620.60	1,461.38
(c) Other Intangible Assets	5.50	4.67
(d) Intangible Assets under Development	23.44	24.69
(e) Financial Assets		
(i) Investments	283.64	253.05
(ii) Other Financial Assets	50.60	45.80
(f) Other Non-current Assets	14.45	45.14
Total Non-current Assets	4,447.72	4,423.74
Current assets		
(a) Inventories	803.83	848.10
(b) Financial Assets		
(i) Trade Receivables	989.17	796.31
(ii) Cash and Cash Equivalents	130.38	131.56
(iii) Bank Balances other than (ii) above	14.14	16.61
(iv) Loans	58.32	59.90
(v) Other Financial Assets	176.43	170.36
(c) Other Current Assets	210.32	253.08
Total Current Assets	2,382.59	2,275.92
Total Assets	6,830.31	6,699.66
EQUITY AND LIABILITIES		
Equity		
(a) Share capital	85.07	85.07
(b) Other equity	2,734.18	2,712.23
Equity Attributable to Owners	2,819.25	2,797.30
Non Controlling Interest	96.12	88.16
Total Equity	2,915.37	2,885.46
Liabilities		
Non-current liabilities		
(a) Financial Liabilities		
(i) Borrowings	1,903.14	1,848.50
(ii) Lease Liabilities	58.01	56.27
(iii) Other Financial Liabilities	7.16	7.15
(b) Non Current Provision	22.62	19.32
(c) Deferred Tax Liabilities (Net)	72.02	73.51
(d) Other Non Current Liabilities	535.47	322.49
Total Non-current Liabilities	2,598.42	2,327.24
Current liabilities		
(a) Financial Liabilities		
(i) Borrowings	769.57	833.03
(ii) Lease Liabilities	2.80	3.72
(iii) Trade Payables	299.67	299.77
(iv) Other Financial Liabilities	143.55	164.06
(b) Other Current Liabilities	67.43	147.35
(c) Provisions	6.58	5.08
(d) Current Tax Liabilities	26.92	33.95
Total Current Liabilities	1,316.52	1,486.96
Total Liabilities	3,914.94	3,814.20
Total Equity and Liabilities	6,830.31	6,699.66

STATEMENT OF UNAUDITED CONSOLIDATED CASH FLOWS FOR THE PERIOD ENDED 30 SEPTEMBER 2023

Amount in ₹ Million

Particulars	Six Month Period Ended	
	30 September 2023	30 September 2022
	Unaudited	Unaudited
A. Cash Flow from operating activities		
Profit before tax	156.75	157.35
Adjustments for:		
Depreciation and amortisation expense	96.83	100.90
Share of profit in joint venture entity	(29.20)	(21.34)
Provision for doubtful debt	6.21	1.85
Bad debts written off	-	0.26
(Profit) / Loss on sale of property, plant & equipment	(0.09)	(0.16)
Amortisation of deferred grant	(36.99)	(39.91)
Interest expense	104.42	15.32
Unrealised foreign exchange loss / (gain)	7.13	21.47
Interest income	(8.54)	(11.25)
Operating profit before working capital changes	296.52	224.50
Adjustments for:		
Trade receivables	(206.20)	(140.16)
Inventories	44.27	(13.53)
Other assets	42.71	(25.62)
Trade payables	(0.10)	85.95
Other liabilities	(70.19)	(32.16)
Provisions	4.80	4.62
Loans	1.58	(0.11)
Other financial liability	(0.45)	1.01
Other financial assets	1.69	2.70
Cash Generated From Operations	114.63	107.21
Income tax paid (net)	(58.10)	(42.80)
Net cash generated from operating activities (A)	56.53	64.41
B. Cash flow from investing activities		
Capital expenditure on Property, Plant and Equipment, including capital advances and capital work-in-progress and on intangible assets	(139.22)	(636.74)
Proceeds from sale of Property, Plant and Equipment	0.18	0.26
Interest received	2.45	2.95
Bank / margin money deposits withdrawn / (Investment) (Net)	(0.67)	8.55
Net cash used in investing activities (B)	(137.26)	(624.97)
C. Cash flow from financing activities		
Proceeds from long term borrowings	197.46	259.06
Repayment of long term borrowings	(109.31)	(22.50)
Proceeds/(Repayment) of Short-term Borrowings (net)	(107.71)	83.92
Government grant received	240.00	240.00
Interest Paid	(62.11)	(20.25)
Dividend Paid	(68.05)	(85.07)
Net cash generated from financing activities (C)	90.28	455.16
Exchange rate fluctuation arising on consolidation (D)	(10.73)	28.71
Net decrease in cash and cash equivalents (A) + (B) + (C) + (D)	(1.18)	(76.69)
Cash and cash equivalents at the beginning of the period	131.56	247.50
Cash and cash equivalents at the end of the period	130.38	170.81

Notes:

- The consolidated financial results of Hester Biosciences Limited (the "Company") and its subsidiaries (together referred as the "Group") and its joint venture entity have been reviewed by the Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 7 November 2023.
- The Statutory Auditors have carried out limited review of the consolidated financial results of the Group for the quarter and six months period ended 30 September 2023.
- Following are the details of consolidated segment wise revenue, results, segment assets and liabilities:

Amount in ₹ Million

Particulars	Quarter Ended			Six Months Period Ended		Year Ended
	30 September 2023	30 June 2023	30 September 2022	30 September 2023	30 September 2022	31 March 2023
Segment Revenue						
a. Poultry Healthcare	366.51	293.09	348.43	659.60	732.34	1,413.19
b. Animal Healthcare	328.63	309.53	378.34	638.16	500.56	1,141.36
c. Petcare	9.41	8.02	4.76	17.43	5.58	17.67
d. Others	-	267.89	-	267.89	-	88.69
Total Revenue from Operations	704.55	878.53	731.53	1,583.08	1,238.48	2,660.91
Segment Results						
a. Poultry Healthcare	45.98	24.21	79.47	70.19	172.10	269.23
b. Animal Healthcare	94.62	23.71	91.82	118.33	49.94	207.35
c. Petcare	(1.33)	(1.68)	(3.37)	(3.01)	(2.90)	(3.99)
d. Others	-	68.87	-	68.87	-	34.37
Total Segment Results	139.27	115.11	167.92	254.38	219.14	506.96
a. Finance costs	80.73	25.70	24.55	106.43	40.56	93.22
b. Share of Profit in Joint Venture Entity	15.49	13.71	5.63	29.20	21.34	44.09
c. Other unallocable expenditure/(income) (Net)	6.40	14.00	46.28	20.40	42.57	56.29
Profit before Tax	67.63	89.12	102.72	156.75	157.35	401.54
Segment Assets						
a. Poultry Healthcare	2,394.03	2,422.04	2,622.65	2,394.03	2,622.65	2,422.77
b. Animal Healthcare	2,071.61	2,051.94	2,147.20	2,071.61	2,147.20	2,142.83
c. Petcare	19.07	13.94	10.57	19.07	10.57	13.86
d. Others	234.59	250.05	-	234.59	-	112.60
Unallocated Assets	2,111.01	1,956.69	1,457.49	2,111.01	1,457.49	2,007.60
Total	6,830.31	6,694.66	6,237.91	6,830.31	6,237.91	6,699.66
Segment Liabilities						
a. Poultry Healthcare	195.80	190.66	207.15	195.80	207.15	273.36
b. Animal Healthcare	230.21	248.84	232.27	230.21	232.27	260.73
c. Petcare	0.19	0.19	0.37	0.19	0.37	0.57
d. Others	13.11	34.76	-	13.11	-	88.36
Unallocated Liabilities	3,475.63	3,271.55	3,090.65	3,475.63	3,090.65	3,191.18
Total	3,914.94	3,746.00	3,530.44	3,914.94	3,530.44	3,814.20

Notes:

- Others segment include sale of other Pharmaceutical products.
- Unallocated assets and liabilities includes capital work in-progress, capital advances and capital creditors related to Human Vaccine Project as the same is yet to be capitalised.

- Key numbers of the standalone financial results of the Company for the quarter and six months period ended 30 September 2023 are as under:

Amount in ₹ Million

Particulars	Quarter Ended			Six Months Period Ended		Year Ended
	30 September 2023	30 June 2023	30 September 2022	30 September 2023	30 September 2022	31 March 2023
Total income	676.53	812.04	741.80	1,488.57	1,259.42	2,593.23
Profit before tax	91.60	87.34	138.79	178.94	206.49	439.24
Profit after tax	67.82	64.71	103.45	132.53	153.50	323.42
Total comprehensive income	68.09	65.00	103.63	133.09	153.28	324.55

The Standalone Financial Results are available at the Company's website www.hester.in and on the website of the stock exchanges www.bseindia.com and www.nseindia.com.

For and on behalf of the Board of Directors


Rajiv Gandhi
 CEO & Managing Director
 DIN: 00438037

 Place: Ahmedabad
 Date: 7 November 2023

Chandulal M. Shah & Co.

CHARTERED ACCOUNTANTS

A/6, 6th Floor, Wing-A, Safal Profitaire, Opp. Prahladnagar Garden, Corporate Road, Prahladnagar, Ahmedabad-380015.
Tel. : 079-2960 1085 • (M) 90330 34430 • E-mail : cms Shah@cms Shah.com • Website : www.cms Shah.com

Independent Auditor's review report on Quarterly Unaudited Standalone Financial Results of Hester Biosciences Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors of
Hester Biosciences Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Hester Biosciences Limited** for the quarter ended on September 30, 2023 and year to date results for the period from April 01, 2023 to September 30, 2023 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed u/s 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in accordance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a Report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognized accounting principles and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed or that it contains any material misstatement.

For Chandulal M. Shah & Co.
Chartered Accountants
FRN No. 101698W

Arpit D. Shah

Arpit D. Shah
Partner

M. No. 135188

UDIN:23135188B6XCMV1186

Place: Ahmedabad

Date: November 07, 2023



Chandulal M. Shah & Co.

CHARTERED ACCOUNTANTS

A/6, 6th Floor, Wing-A, Safal Profitaire, Opp. Prahladnagar Garden, Corporate Road, Prahladnagar, Ahmedabad-380015.
Tel. : 079-2960 1085 • (M) 90330 34430 • E-mail : cmshah@cmshah.com • Website : www.cmshah.com

Independent Auditor's review report on Quarterly Unaudited Consolidated financial results of Hester Biosciences Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors of
Hester Biosciences Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results of Hester Biosciences Limited (the "Holding company") and its subsidiaries and joint venture entity (the Holding, its subsidiaries and joint venture entity together referred to as the "Group") for the quarter ended on September 30, 2023 and year to date results for the period April 01, 2023 to September 30, 2023 (the "Statement"), attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed u/s 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a Report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
We have also performed procedures in accordance with the Circular No. CIR/CFD/CMDI/44/2019 dated March 29, 2019, issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.
4. The statement includes the results of the following subsidiaries and joint venture:

Sr. No.	Name of the Company	Relationship
1	Texas Lifesciences Private Limited	Subsidiary
2	Hester Biosciences Nepal Private Limited	Subsidiary
3	Hester Biosciences Africa Limited	Subsidiary
4	Hester Biosciences Kenya Limited	Subsidiary
5	Hester Biosciences Tanzania Limited	Subsidiary
6	Thrishool Exim Limited	Joint Venture Entity

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognized accounting principles and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



6. The unaudited consolidated financial results include the interim financial statements of 2 subsidiaries which have been reviewed by other auditors, whose interim financial statements reflect total assets of INR 565.45 million as at September 30, 2023, total income of INR 66.15 million and INR 168.68 million, total net profit / (loss) after tax of INR (2.60) million and INR 34.74 million and total comprehensive income / (loss) of INR (2.60) million and of INR 34.74 million for the quarter ended on September 30, 2023 and for the period from April 01, 2023 to September 30, 2023 respectively and net cash inflow / (outflow) of INR 50.86 million for the period from April 01, 2023 to September 30, 2023 as considered in the consolidated unaudited financial results. The interim financial statements of these subsidiaries have been reviewed by the other auditors whose reports have been furnished to us, and our conclusion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the report of such other auditors and the procedures performed by us as stated in paragraph 3 above.
7. The unaudited consolidated financial results include the interim financial statements of 3 subsidiaries which have not been reviewed by their auditors, whose interim financial statements reflect total assets of INR 1,228.50 million as at September 30, 2023, total income of INR 61.11 million and INR 95.25 million, total net profit / (loss) after tax of INR (47.06) million and INR (94.13) million and total comprehensive income / (loss) of INR (51.10) million and of INR (98.55) million for the quarter ended on September 30, 2023 and for the period from April 01, 2023 to September 30, 2023 respectively and net cash inflow / (outflow) of INR (25.36) million for the period from April 01, 2023 to September 30, 2023 as considered in the consolidated unaudited financial results. The management has certified these financial statements and other financial information.
8. The accompanying Statement includes the group's share of Net Profit after tax of INR 15.49 million and INR 29.20 million for the quarter ended on September 30, 2023 and for the period from April 01, 2023 to September 30, 2023 respectively, in respect of the joint venture entity. The management has certified these interim financial statements and other financial information of the joint venture entity.
9. Certain of these subsidiaries and joint venture entity are located outside India whose financial results have been prepared in accordance with accounting principles generally accepted in their respective countries ('local GAAP'). The Holding Company's management has converted the financial results of such subsidiaries and joint venture entity from local GAAP to accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Holding Company's management. Our conclusion, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and joint venture entity, is based on the conversion adjustments prepared by the management of the Holding Company and reviewed by us.

Our conclusion on the statement in respect of the matters stated in paragraph 6, 7, 8 and 9 above is not modified with respect to our reliance on the work done and the reports of the other auditors and the financial statements and financial information certified by the Management.

For Chandulal M. Shah & Co.
Chartered Accountants
FRN No. 101698W



Arpit D. Shah
Partner

Place: Ahmedabad
Date: November 07, 2023

M. No. 135188
UDIN: 23135188BGXCMW1889



Press Release

7 November 2023

Hester Biosciences Q2 & H1 FY24 Results

H1 FY24 Standalone and Consolidated Revenue up by 20% and 28%, respectively

Q2 FY24 Standalone and Consolidated Revenue down by 8% and 4%, respectively

Hester today announced the unaudited financial results for Q2 & H1 FY24.

Standalone Financial Highlights

Revenues

(₹ Million)

Division	Q2			H1		
	FY24	FY23	Change %	FY24	FY23	Change %
Animal Healthcare	304.70	360.75	-16%	529.36	481.51	10%
Poultry Healthcare	339.59	354.52	-4%	642.47	698.73	-8%
Petcare	9.41	4.76	98%	17.43	5.58	212%
Others*	-	-	-	267.89	-	100%
Product Sales	653.70	720.03	-9%	1,457.15	1,185.82	23%
License & services fees	10.63	-	100%	10.63	39.49	-73%
Revenue from Operations	664.33	720.03	-8%	1,467.78	1,225.31	20%

* includes exports of other pharmaceutical products

Animal Healthcare Division

- In Q2 FY24, the Animal Healthcare division experienced a 16% decline in sales mainly due to the uneven sales of Goat Pox Vaccine. There was an unprecedented surge in demand for the Goat Pox Vaccine (GPV) in Q1 FY23 in response to an outbreak of Lumpy Skin Disease (LSD) in cattle.
- It is important to note that, GPV sales got distributed across both quarters of H1 FY24, in contrast to the previous year where the GPV sales were concentrated in Q2. The overall sales of GPV for H1 FY24 have maintained consistency with figures from H1 FY23.

Poultry Healthcare Division

In Q2 FY24, the Poultry Healthcare division saw a 4% decrease in overall sales.

- Domestic vaccine sales experienced a growth of 6%, marking a significant turnaround after six consecutive quarters of decline, attributable to improved sales operations and better farm economics.
- In contrast, there was a substantial 43% reduction in export sales. This decline in exports was attributed to foreign exchange constraints in African countries, thereby reducing their purchasing ability, which led to the degrowth.

Petcare Division

The Petcare division, launched last year, has demonstrated impressive performance in Q2 FY24, achieving sales of ₹9.41 Million, growing 98% as compared to Q2 FY23. This achievement is attributed to a consistent trend in the Petcare segment, driven by successful expansion and increased market penetration into new territories.

Profitability Analysis

(₹ Million)

Particulars	Q2			H1		
	FY24	FY23	Change %	FY24	FY23	Change %
Gross Profit margin	69%	69%	-	61%	68%	-7%
EBITDA	119.93	157.82	-24%	233.58	249.80	-6%
PAT	67.82	103.45	-34%	132.53	153.50	-14%
EPS (In ₹, not annualised)	7.97	12.16	-34%	15.58	18.04	-14%

- Overall gross profit margin was maintained at 69% in Q2 FY24.
- EBITDA and PAT de-grew by 24% and 34%, respectively in Q2 FY24 due to various factors:
 - Further rationalization of product mix.
 - Withdrawal of 2 products in Animal Healthcare division due to change in drug regulations.
 - The overall focus to increase the sales of health products in both the divisions to address a wider market.

Product segment updates:

Vaccines sales:

- All states in India have initiated an immunization program targeting Lumpy Skin Disease through the Goat Pox Vaccine. The distribution of supplies of GPV has commenced, and we anticipate selling between 30 to 35 million doses over the course of the next two quarters.
- In Q1 FY24, Hester initiated the distribution of PPR vaccines as part of the National Immunization program. The contract entails the supply of 300 million doses of PPR vaccine, with completion expected by October 2024.

Health products sales

- The sales of our health products were affected by the discontinuation of two of our brands - CurX injection and iSumovet. This decision was a result of the change in drug regulations, which prohibited the use of Ketoprofen for animal purposes. The combined sales of these two products amounted to ₹50 million in FY23.
- To address the above, we launched a new product CurX LA, which is a substitute CurX in this month, and the substitute of iSumovet is expected to be launched in Q3. These two products are expected to recoup the sales loss arising from withdrawal of above brands.
- Overall the company has decided to aggressively pursue the sales and marketing of health products in both the divisions to address a wider market.

Consolidated Financial Highlights

(₹ Million)

Particulars	Q2			H1		
	FY24	FY23	Change %	FY24	FY23	Change %
Revenue from operations	704.55	731.53	-4%	1,583.08	1,238.48	28%
EBITDA	132.12	127.45	4%	275.75	201.75	37%
PAT (excl. OCI)	40.41	66.03	-39%	107.51	101.63	6%
EPS (In ₹, not annualized)	4.75	7.77	-39%	12.64	11.95	6%

Consolidated results include operations of subsidiaries from Nepal and Tanzania

- Hester Nepal had a turnover of ₹7.28 million in Q2 FY24, primarily from domestic sales of vaccines with overall Net Loss of ₹7.05 million. The over all impact of exports and international tenders has also been felt at Nepal but we are neutralizing that impact by focusing on domestic business which is showing a lot of potential.
- Hester Africa has continued with export sales aggregating to ₹19.58 million in Q2 FY24 with overall loss of ₹49.17 million, arising primarily on account of foreign exchange fluctuation on borrowings.
 - The plant is ready with 6 vaccines registered and another 5 on way to be registered by the end of this financial year. The much awaited harmonization of registration process is under implementation, which will then enable us to start marketing our vaccines immediately to other East African countries, a process which was supposed to have been implemented over a year ago within the East African community.
 - The weaker purchasing power of African countries has currently resulted into lesser sales.
- Hester's share of profit in joint venture entity, Thrishool Exim Limited, Tanzania has increased in Q2 FY24 by ₹9.86 million.

Way Forward

We are conscious of the reduction in the bottom line and are working towards restoring the same.

Initiatives towards this action are:

Short term:

1. Boost sales and improve productivity per sales person
2. Give a push for exports from all the three plants
3. Work towards production efficiency

Middle term:

Repurpose the BSLIII Laboratory from manufacturing the Drug Substance of Covid vaccine to human or other veterinary vaccines

Long term:

Focus on R&D to develop next generation vaccines, new vaccines

**Hester Biosciences Limited****Head Office**

Pushpak, 1st Floor
Panchvati Circle
Motilal Hirabhai Road
Ahmedabad 380006
Gujarat, India
Phone +91 79 26445106

Factory

Village Merda-Ardraj
Taluka Kadi
District Mehsana
Gujarat 382721, India
Phone +91 2764 285 502
+91 2764 285 453

Email mail@hester.in
Toll Free 1 800 233 7937
www.hester.in

CIN L99999GJ1987PLC022333

About Hester Biosciences Limited:

Hester Biosciences Limited is one of the India's leading animal health company, manufacturing vaccines and health products since 1997. Hester has three divisions:

1. Poultry Healthcare division
2. Animal Healthcare division
3. Petcare division

- It is the world's largest manufacturer and supplier of PPR vaccine, having approximately 75% of the world market.
- It has over 90% market share in Goat Pox vaccine in India which is being used to immunise cattle against Lumpy Skin disease.
- It is the second largest poultry vaccine manufacturer, with approximately 35% market share in India.

Hester's vaccine capabilities include multiple platforms such as Chick Embryo Origin, Continuous Cell line, Tissue Culture and Fermentation based live as well as inactivated vaccines.

Hester recognises the vision of ONE HEALTH, and works on improving the health of animals by enabling better health for human beings.

For more information, please visit www.hester.in